@article {2019,
	title = {Calpains as mechanistic drivers and therapeutic targets for ocular disease.},
	journal = {Trends Mol Med},
	volume = {28},
	year = {2022},
	month = {2022 08},
	pages = {644-661},
	abstract = {<p>Ophthalmic neurodegenerative diseases encompass a wide array of molecular pathologies unified by calpain dysregulation. Calpains are calcium-dependent proteases that perpetuate cellular death and inflammation when hyperactivated. Calpain inhibition trials in other organs have faced pharmacological challenges, but the eye offers many advantages for the development and testing of targeted molecular therapeutics, including small molecules, peptides, engineered proteins, drug implants, and gene-based therapies. This review highlights structural mechanisms underlying calpain activation, distinct cellular expression patterns, and in vivo models that link calpain hyperactivity to human retinal and developmental disease. Optimizing therapeutic approaches for calpain-mediated eye diseases can help accelerate clinically feasible strategies for treating calpain dysregulation in other diseased tissues.</p>
},
	keywords = {Calcium, Calpain, Cell Death, Humans, Retina},
	issn = {1471-499X},
	doi = {10.1016/j.molmed.2022.05.007},
	author = {Vu, Jennifer T and Wang, Elena and Wu, Jolan and Sun, Young Joo and Velez, Gabriel and Bassuk, Alexander G and Lee, Soo Hyeon and Mahajan, Vinit B}
}
